Insider Transactions in Q3 2021 at Schrodinger, Inc. (SDGR)
Insider Transaction List (Q3 2021)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 15
2021
|
Karen Akinsanya President of R&D, Therapeutics |
SELL
Open market or private sale
|
Direct |
1,394
-100.0%
|
$85,034
$61.13 P/Share
|
Sep 15
2021
|
Karen Akinsanya President of R&D, Therapeutics |
BUY
Exercise of conversion of derivative security
|
Direct |
1,394
+50.0%
|
$5,576
$4.34 P/Share
|
Sep 13
2021
|
Robert Lorne Abel Officer |
SELL
Open market or private sale
|
Direct |
15,602
-68.65%
|
$951,722
$61.62 P/Share
|
Sep 13
2021
|
Robert Lorne Abel Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,602
+50.0%
|
$265,234
$17.0 P/Share
|
Sep 02
2021
|
Joel Lebowitz EVP & CFO |
SELL
Open market or private sale
|
Direct |
3,874
-100.0%
|
$247,936
$64.62 P/Share
|
Sep 02
2021
|
Joel Lebowitz EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,874
+50.0%
|
$15,496
$4.34 P/Share
|
Sep 01
2021
|
Joel Lebowitz EVP & CFO |
SELL
Open market or private sale
|
Direct |
1,700
-100.0%
|
$108,800
$64.53 P/Share
|
Sep 01
2021
|
Joel Lebowitz EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+50.0%
|
$6,800
$4.34 P/Share
|
Aug 16
2021
|
Karen Akinsanya President of R&D, Therapeutics |
SELL
Open market or private sale
|
Direct |
37,738
-78.74%
|
$2,151,066
$57.8 P/Share
|
Aug 16
2021
|
Karen Akinsanya President of R&D, Therapeutics |
BUY
Exercise of conversion of derivative security
|
Direct |
37,738
+30.27%
|
$301,904
$8.19 P/Share
|
Aug 02
2021
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
12,000
-32.42%
|
$816,000
$68.27 P/Share
|
Jul 19
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
63,061
-0.26%
|
$4,225,087
$67.64 P/Share
|
Jul 16
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
29,000
-0.16%
|
$1,914,000
$66.94 P/Share
|
Jul 15
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
59,358
-0.32%
|
$3,917,628
$66.63 P/Share
|
Jul 14
2021
|
Joel Lebowitz EVP & CFO |
SELL
Open market or private sale
|
Direct |
5,574
-78.34%
|
$379,032
$68.44 P/Share
|
Jul 14
2021
|
Joel Lebowitz EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,574
+50.0%
|
$22,296
$4.34 P/Share
|
Jul 14
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
34,051
-0.18%
|
$2,315,468
$68.45 P/Share
|
Jul 13
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
51,213
-0.16%
|
$3,636,123
$71.64 P/Share
|
Jul 12
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,930
-0.11%
|
$1,569,750
$75.22 P/Share
|
Jul 09
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,514
-0.07%
|
$638,550
$75.56 P/Share
|
Jul 08
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
48,410
-0.13%
|
$3,533,930
$73.4 P/Share
|
Jul 07
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
32,849
-0.13%
|
$2,397,977
$73.89 P/Share
|
Jul 06
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
25,230
-0.13%
|
$1,892,250
$75.5 P/Share
|
Jul 02
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
18,613
-0.1%
|
$1,414,588
$76.2 P/Share
|
Jul 01
2021
|
David E Shaw > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
41,575
-0.21%
|
$3,159,700
$76.52 P/Share
|